Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;21(6):746-751.
doi: 10.17305/bjbms.2020.5329.

Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data

Sibel Oyucu Orhan  1 , Ahmet Bilgehan Sahin  1 , Erdem Cubukcu  1 , Adem Deligonul  1 , Birol Ocak  1 , Bedrettin Orhan  2 , Turkkan Evrensel  1
Affiliations

Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data

Sibel Oyucu Orhan et al. Bosn J Basic Med Sci. .

Abstract

Kaposi sarcoma is a rare disease and there is a gap in the literature about which chemotherapeutics should be applied, especially for the classical type. We aimed to present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 Kaposi sarcoma (KS) patients treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics, and the chemotherapeutic agents administered to the 16 KS patients diagnosed in our center and treated with chemotherapy, based on the medical records obtained. The median age, gender, type of KS, site of involvement, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4-85.8 years). Among the patients, 1 had immunosuppression-related KS, 4 had AIDS-related KS, and 11 had classical KS. In the first-line cytotoxic therapy, 7 patients received pegylated-liposomal doxorubicin (PLD), 6 patients received paclitaxel, 2 patients received oral etoposide, and 1 patient received the adriamycin, bleomycin, and vincristine regimen. In the Kaplan-Meier analysis, the PFS was 39.9 months (95% CI, 7.7-72.0). In the first-line setting, a significant difference in terms of PFS was observed between the PLD- and paclitaxel-treated groups (not reached vs. 12.8 months, p = 0.033). The OS was 66.1 months (95% CI, 30.2-102.0). The ORR of the 16 patients was 43.8%, and their DCR was 81.3%. No grade 3 or 4 toxicity was observed. This retrospective study showed that PLD seems better than paclitaxel in terms of PFS and response rates and it has shown to have a good safety profile in KS patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Kaplan Meier curve of progression-free survival of patients
Figure 2
Figure 2
Progression-free Survival; Visceral involvement vs Other
Figure 3
Figure 3
Progression-free Survival; Pegylated Liposomal Doxorubicin (PLD) vs Paclitaxel
Figure 4
Figure 4
Kaplan Meier curve of overall survival of patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Di Lorenzo G, Di Trolio R, Montesarchio V, Palmieri G, Nappa P, Delfino M, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma:A retrospective study. Cancer. 2008;112(5):1147–52. - PubMed
    1. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med. 1996 Jul 25;335(4):233–41. - PubMed
    1. Sternbach G, Varon J. Moritz Kaposi:Idiopathic pigmented sarcoma of the skin. J Emerg Med. 1995;13(5):671–4. - PubMed
    1. Karakas Y, Aksoy S, Gullu HI. Kaposi's Sarcoma Epidemiology, Risk Factors, Staging and Treatment:AN OVERVIEW. Acta Oncol Tur. 2017;50(2):148–59.
    1. Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma:a systematic review of the literature. J Am Acad Dermatol. 2013 Feb;68(2):313–31. - PubMed

Supplementary concepts